CTIC CTI BioPharma Corp.

5.01
+0.04  (0.8%)
Previous Close 4.97
Open 4.92
Price To book 7.78
Market Cap 140.29M
Shares 28,001,000
Volume 587,216
Short Ratio 0.18
Av. Daily Volume 851,914

SEC filingsSee all SEC filings

  1. 8-K - Current report 17539047
  2. 8-K - Current report 17515676
  3. 8-K - Current report 17510983
  4. 8-A12G/A [Amend] - Registration of securities [Section 12(g)] 17502928
  5. 8-K - Current report 162069325

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Top-line data from confirmatory trial required for full EMA approval due by end of 2017.
PIXUVRI
B-cell non-Hodgkin lymphoma
PERSIST-2 data released August 2016. One of two primary endpoints met. Announced January 5, 2017 removal of clinical hold. Additional trial to commence 2Q 2017.
Pacritinib
Myelofibrosis
Phase 3 trial potentially in the pipeline.
Tosedostat
Older patients with AML or high-risk myelodysplastic syndrome (MDS) - cancer
Phase 3 - noted July 2016 that unlikely to have survival benefit
OPAXIO
Ovarian cancer

Latest News

  1. 6:11 pm CTI BioPharma regained compliance with Nasdaq Listing Rule for minimum bid price; matter is now closed
  2. CTI BIOPHARMA CORP Files SEC form 8-K, Other Events
  3. Latest Reports on Recent Market Movers: 3D Systems and CTI BioPharma
  4. CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
  5. CTI BioPharma Announces Progress Of Lead Programs And Strategic Objectives For 2017
  6. CTI Biopharma stock revived after FDA ruling, reverse stock split
  7. CTI BIOPHARMA CORP Files SEC form 8-K, Material Modification to Rights of Security Holders
  8. Why CTI BioPharma Corp. Stock Popped Today
  9. CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib
  10. ETFs with exposure to CTI BioPharma Corp. : January 4, 2017
  11. CTI BioPharma Corp. breached its 50 day moving average in a Bullish Manner : CTIC-US : January 4, 2017
  12. CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
  13. CTI BIOPHARMA CORP Files SEC form 8-K, Material Modification to Rights of Security Holders
  14. ETFs with exposure to CTI BioPharma Corp. : December 13, 2016
  15. Do Hedge Funds Love Manning and Napier Inc (MN)?
  16. CTI BIOPHARMA CORP Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  17. PERSIST-2 Phase 3 Study Of Pacritinib Versus Best Available Therapy Shows Encouraging Clinical Activity In High-Risk Patients With Advanced Myelofibrosis In Late-Breaking Session At ASH Annual Meeting
  18. ETFs with exposure to CTI BioPharma Corp. : December 2, 2016
  19. CTI BioPharma Presents Nonclinical Pharmacology Study Demonstrating Pacritinib Has Distinct Profile Amongst JAK Inhibitors At EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium
  20. CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan

SEC Filings

  1. 8-K - Current report 17539047
  2. 8-K - Current report 17515676
  3. 8-K - Current report 17510983
  4. 8-A12G/A [Amend] - Registration of securities [Section 12(g)] 17502928
  5. 8-K - Current report 162069325
  6. 8-K - Current report 162064669
  7. 8-K - Current report 162044740
  8. 8-K - Current report 162025822
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 161981835
  10. 8-K - Current report 161981468